Funded by the U.S. National Institutes of Health in 2009, CHARM is an $11 million, five year, multicenter grant intended to advance candidate rectal microbicides from discovery into early clinical development. Rather than simply testing existing vaginal formulations of microbicides, CHARM seeks to develop rectal-specific products from the beginning.
Find out the latest on CHARM, including the development of a purely rectal formulation of tenofovir gel, and other scientific activities underway and planned.
CHARMed, for sure!
Click here to determine the time of the call in your location.
Slides will be made available on the IRMA website here , for download in advance of the teleconference, and via the ReadyTalk web interface on the day of the call. Audio for the call will be available via phone only.
We look forward to your participation in this global teleconference!
*Join IRMA’s robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at email@example.com. Joining our listserv automatically makes you a member of IRMA – a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.
*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.
*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article’s content.